|
Scientific Advisory Board
Charles J. Decedue, Ph. D. trained as a microbiologist,
he began his association with the University of Kansas in
1976 as Director of the Biochemical Research Service Laboratory.
In 1989, Decedue assumed the position of Executive Director
of the Higuchi Biosciences Center. The Higuchi Biosciences
Center has the dual mission of enhancing the University’s
environment for basic biomedical research and advancing the
commercial development of the results of that research. Companies
launched from activities of the Higuchi Biosciences Center
include Oread Laboratories, Inc., CyDex, Inc., ProQuest Pharmaceuticals,
Inc., CritiTech, Inc., BioScience Innovations, Inc., and Admunex,
Inc. Decedue has over 30 years experience as a research scientist
and administrator.
Valentino J. Stella, Ph. D. is a Distinguished
Professor of Pharmaceutical Chemistry at the University of
Kansas. His research centers on the application of physical/organic
chemistry to the study of factors affecting drug delivery.
Dr. Stella is known for his work in improving drug stability
and solubility especially as these relate to the preformulation
of anticancer and antiAIDS drugs. He also studies the use
of prodrugs to overcome problems of solubility and stability
and is the inventor of fosphenytoin, a safe injectable form
of sodium phenytoin. Current research on prodrugs include
the use of prodrugs with greater safety profiles compared
to the parent molecules, drug targeting via prodrugs, and
novel prodrugs of tertiary amines, hindered alcohols, phenols,
imides, and amides. He is also studying the use of novel cyclodextrins
that can be used safely in parenteral formulations as well
as for oral applications. His work led to the discovery of
Captisol™.
Roger A. Rajewski, Ph. D. is currently Director
at the Biotechnology Innovation & Optimization Center
(BIOC) at the University of Kansas (KU). He has been involved
in the Kansas Technology Enterprise Corporation-supported
development of University of Kansas technologies for potential
commercialization in the private sector. During his tenure
at BIOC, Dr. Rajewski has helped guide the development of
two additional technologies: drug processing with supercritical
fluids and novel prodrug technologies. Multiple patents in
both these areas have been or are being secured by the University
for CritiTech, Inc., and the prodrug technologies have been
licensed to ProQuest Pharmaceuticals, Inc. In addition, BIOC
has provided technical input for three Kansas companies not
associated with the University. Dr. Rajewski has a Ph.D in
Pharmaceutical Chemistry from the University of Kansas.
Bala Subramaniam, Ph. D. is a co-founder
of CritiTech. He is currently the Dan F. Servey Distinguished
Professor of Chemical and Petroleum Engineering and the Director
of the National Science Foundation Engineering Research Center
for Environmentally Beneficial Catalysis at the University
of Kansas (KU). Dr. Subramaniam obtained a Bachelor's degree
in chemical engineering from the University of Madras, India
and a Ph. D. degree in chemical engineering from the University
of Notre Dame. He joined the KU chemical and petroleum engineering
department in 1985, and recently served as chair of his department.
He has held visiting Professorships at the Institute of Process
Engineering, ETH in Zurich (Switzerland), University of Nottingham
(UK) and at the University of California, Davis. Dr. Subramaniam's
primary research interests are in catalysis, reaction engineering
and crystallization, with emphasis on developing sustainable
processes.. In recent years, his research has focused on systematically
exploiting the tunable physical and transport properties of
CO2-based solvents in developing novel catalytic, particle
formation and particle coating processes. He has authored
100+ research publications including 12 patents, presented
invited seminars at 70+ universities and companies, and delivered
keynote/plenary lectures at 20+ international conferences.
Dr. Subramaniam has received several awards for his teaching
and research, including the Dow Outstanding Young Faculty
Award from the American Society for Engineering Education;
the Gould Award for Teaching and the Miller Award for Research
from the KU School of Engineering; the Silver Anniversary
Teaching Award from the University of Kansas, and a Higuchi
Research Achievement Award from KU, the highest recognition
for research given by the University of Kansas. 
Charles Russell Middaugh, Ph. D. is currently
the Aya and Takeru Higuchi Distinguished Professor of Pharmaceutical
Chemistry at the University of Kansas. Dr. Middaugh received
his Ph.D. in biochemistry from Cornell University in 1978.
Before joining the University of Kansas, he was a Senior Scientist
for Pharmaceutical Research, Vaccine Division, and Department
of Human Genetics at Merck & Co. Previous to his employment
with Merck & Co., Dr. Middaugh was a Visiting Scientist
at the Massachusetts Institute of Technology, Physics Dept,
and a professor at the University of Wyoming for ten years.
Dr. Middaugh is currently an Associate Editor (Biotechnology)
for the Journal of Pharmaceutical Sciences and on the Editorial
Board for the Journal of Biological Chemistry. He also serves
as a Faculty Fellow for the Honors Program at the University
of Kansas. Dr. Middaugh has received many awards, distinctions,
and is often a keynote speaker in the field of biochemistry.
So far in 2007, he has over 20 publications, not including
patents and abstracts.
David Johnston - (detail coming soon)
|
